MindBio Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Justin Hanka
Chief executive officer
AU$53.7k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 3.6yrs |
| CEO ownership | 5.7% |
| Management average tenure | no data |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -AU$274k |
| Jun 30 2024 | AU$54k | AU$54k | -AU$416k |
Compensation vs Market: Justin's total compensation ($USD33.50K) is below average for companies of similar size in the German market ($USD467.65K).
Compensation vs Earnings: Insufficient data to compare Justin's compensation with company performance.
CEO
Justin Hanka (51 yo)
3.6yrs
Tenure
AU$53,691
Compensation
Mr. Justin Adam Hanka, B.Bus, Grad Dip. Fin, serves as Non-Executive Chairman of Sparc Al Inc (formerly known as EYEFI Group Technologies Inc.) since December 15, 2022. He was Chairman of Blackhawk Growth...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co Founder | 3.6yrs | AU$53.69k | 5.66% € 102.2k | |
| Independent Chairman | 3.5yrs | no data | no data | |
| Independent Non Executive Director | 3.5yrs | no data | 0.099% € 1.8k |
3.5yrs
Average Tenure
55yo
Average Age
Experienced Board: WF6's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:33 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MindBio Therapeutics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|